Results 11 to 20 of about 577,742 (361)
Pediatric acute lymphoblastic leukemia
Haematologica, 2020 The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute lymphoblastic leukemia (ALL), the development of experimental models to probe mechanisms and evaluate new therapies, and the development of more efficacious treatment stratification.
Charles G. Mullighan, Hiroto Inaba
openaire +6 more sources
Acute Lymphoblastic Leukemia in Children [PDF]
New England Journal of Medicine, 2015 The most common cancer in childhood is now curable in 90% of patients. Current efforts are focused on devising molecular-based therapy for the subsets of acute lymphoblastic leukemia that are most resistant to current therapy.
Hunger, S.P., Mullighan, C.G.
openaire +5 more sources
Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
Journal of Clinical Medicine, 2021 The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably during the last five decades. Such improvements were made possible by the incorporation of new diagnostic technologies, the effective administration of conventional ...
H. Inaba, C. Pui
semanticscholar +1 more source
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2021 The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for ...
P. Brown +31 more
semanticscholar +1 more source
Cancer Discovery, 2021 Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may allow targeting of both BCL-2 and BCL XL without dose-limiting thrombocytopenia associated with navitoclax monotherapy.
V. Pullarkat +28 more
semanticscholar +1 more source
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
New England Journal of Medicine, 2020 BACKGROUND Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment.
R. Foà +19 more
semanticscholar +1 more source
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia
New England Journal of Medicine, 2018 Background In a single‐center phase 1–2a study, the anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and ...
S. Maude +34 more
semanticscholar +1 more source
Hybrid Inception v3 XGBoost Model for Acute Lymphoblastic Leukemia Classification
Computational and Mathematical Methods in Medicine, 2021 Acute lymphoblastic leukemia (ALL) is the most common type of pediatric malignancy which accounts for 25% of all pediatric cancers. It is a life-threatening disease which if left untreated can cause death within a few weeks.
S Ramaneswaran +3 more
semanticscholar +1 more source
MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia
Haematologica, 2014 T-cell acute lymphoblastic leukemia arises from the leukemic transformation of developing thymocytes and results from cooperative genetic lesions. Inactivation of the PHF6 gene is frequently observed in T-cell acute lymphoblastic leukemia, suggesting an ...
Evelien Mets +15 more
doaj +1 more source
Haematologica, 2018 Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity.
Ibrahim Aldoss +20 more
doaj +1 more source